Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LINC-4: Osilodrostat in Cushing's Disease
NCT02697734Phase 3Completed
- Sponsor
- Novartis
- Start
- Oct 2016
- Primary completion
- Jun 2019
- Modality
- Small Molecules
- Countries
- 14
01
Overview
A Phase 3 trial of osilodrostat in Cushing's disease (CD), sponsored by Novartis. Started Oct 2016; status: completed.
02
Drugs
osilodrostat
03
Conditions
Cushing's disease (CD)
Beyond the preview
Go deeper on NCT02697734.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02697734.